Factors that explain excretion of enteric pathogens by persons without diarrhea

Clinical Infectious Diseases

Volumn 55, Issue SUPPL. 4, 2012, Pages

  Levine, Myron M ^a   Robins Browne, Roy M ^b,c  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

TRACE ELEMENT;

ACUTE DIARRHEA; ARTICLE; BACTERIAL STRAIN; CAMPYLOBACTER JEJUNI; CHOLERA; DIAGNOSTIC TEST; DIARRHEA; ENTEROPATHOGENIC ESCHERICHIA COLI; ENTEROPATHY; ENTEROTOXIGENIC ESCHERICHIA COLI; ENVIRONMENTAL FACTOR; EXCRETION; GENETIC HETEROGENEITY; GENOTYPE; GIARDIA LAMBLIA; HOST SUSCEPTIBILITY; HUMAN; INNATE IMMUNITY; INTESTINE FLORA; NONHUMAN; NOROVIRUS INFECTION; PATHOGENICITY; PREVALENCE; PRIORITY JOURNAL; VIBRIO CHOLERAE;

ASYMPTOMATIC DISEASES; DIARRHEA; DISEASE SUSCEPTIBILITY; FECES; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; INTESTINAL MUCOSA; MILK, HUMAN;

EID: 84870033212     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis789     Document Type: Article

References (87)

1. Bruzzi P, Green SB, Byar DP, Brinton LA, Schairer C. Estimating the population attributable risk for multiple risk factors using case-control data. Am J Epidemiol 1985; 122:904-14. (Pubitemid 16207356)
2. Black RE, Lopez de Romana G, Brown KH, Bravo N, Bazalar OG, Kanashiro HC. Incidence and etiology of infantile diarrhea and major routes of transmission in Huascar, Peru. Am J Epidemiol 1989; 129:785-99. (Pubitemid 19094256)
3. Steinsland H, Valentiner-Branth P, Perch M, et al. Enterotoxigenic Escherichia coli infections and diarrhea in a cohort of young children in Guinea-Bissau. J Infect Dis 2002; 186:1740-7. (Pubitemid 35463506)
4. Hasan KZ, Pathela P, Alam K, et al. Aetiology of diarrhoea in a birth cohort of children aged 0-2 year(s) in rural Mirzapur, Bangladesh. J Health Popul Nutr 2006; 24:25-35. (Pubitemid 43984536)
5. Ferreccio C, Prado V, Ojeda A, et al. Epidemiologic patterns of acute diarrhea and endemic Shigella infections in a poor periurban setting in Santiago, Chile. Am J Epidemiol 1991; 134:614-27.
6. Levine MM, Ferreccio C, Prado V, et al. Epidemiologic studies of Escherichia coli infections in a low socioeconomic level periurban community in Santiago, Chile. Am J Epidemiol 1993; 138:849-69. (Pubitemid 23357816)
7. Buchwald DS, Blaser MJ. A review of human salmonellosis: II. Duration of excretion following infection with nontyphi Salmonella. Rev Infect Dis 1984; 6:345-56.
8. Smith ER, Badley BW. Treatment of Salmonella enteritis and its effect on the carrier state. Can Med Assoc J 1971; 104:1004-6.
9. Tribble DR, Baqar S, Scott DA, et al. Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans. Infect Immun 2010; 78:1750-9.
10. Salazar-Lindo E, Sack RB, Chea-Woo E, et al. Early treatment with erythromycin of Campylobacter jejuni-associated dysentery in children. J Pediatr 1986; 109:355-60. (Pubitemid 16032540)
11. Robins-Browne RM, Mackenjee MK, Bodasing MN, Coovadia HM. Treatment of Campylobacter-associated enteritis with erythromycin. Am J Dis Child 1983; 137:282-5. (Pubitemid 13143092)
12. Porter IA, Reid TM. A milk-borne outbreak of Campylobacter infection. J Hyg (Lond) 1980; 84:415-9. (Pubitemid 10092965)
13. Partridge DG, Evans CM, Raza M, Kudesia G, Parsons HK. Lessons from a large norovirus outbreak: impact of viral load, patient age and ward design on duration of symptoms and shedding and likelihood of transmission. J Hosp Infect 2012; 81:25-30.
14. Aoki Y, Suto A, Mizuta K, Ahiko T, Osaka K, Matsuzaki Y. Duration of norovirus excretion and the longitudinal course of viral load in norovirus- infected elderly patients. J Hosp Infect 2010; 75:42-6.
15. Henke-Gendo C, Harste G, Juergens-Saathoff B, Mattner F, Deppe H, Heim A. New real-time PCR detects prolonged norovirus excretion in highly immunosuppressed patients and children. J Clin Microbiol 2009; 47:2855-62.
16. Atmar RL, Opekun AR, Gilger MA, et al. Norwalk virus shedding after experimental human infection. Emerg Infect Dis 2008; 14:1553-7.
17. Levine MM, DuPont HL, Khodabandelou M, Hornick RB. Long-term Shigella-carrier state. N Engl J Med 1973; 288:1169-71.
18. Levine M, Kaper J, Black RE, Clements M. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev 1983; 47:510-50. (Pubitemid 14210910)
19. DuPont HL, Formal SB, Hornick RB, et al. Pathogenesis of Escherichia coli diarrhea. N Engl J Med 1971; 285:1-9.
20. Levine MM, Nalin DR, Hoover DL, Bergquist EJ, Hornick RB, Young CR. Immunity to enterotoxigenic Escherichia coli. Infect Immun 1979; 23:729-36. (Pubitemid 9138978)
21. Levine MM, Caplan ES, Waterman D, Cash RA, Hornick RB, Snyder MJ. Diarrhea caused by Escherichia coli that produce only heat- stable enterotoxin. Infect Immun 1977; 17:78-82. (Pubitemid 8130629)
22. Lumish RM, Ryder RW, Anderson DC, Wells JG, Puhr ND. Heatlabile enterotoxigenic Escherichia coli induced diarrhea aboard a Miami-based cruise ship. Am J Epidemiol 1980; 111:432-6. (Pubitemid 10021499)
23. Evans DG, Satterwhite TK, Evans DJ Jr., DuPont HL. Differences in serological responses and excretion patterns of volunteers challenged with enterotoxigenic Escherichia coli with and without the colonization factor antigen. Infect Immun 1978; 19:883-8.
24. Satterwhite TK, Evans DG, DuPont HL, Evans DJ Jr. Role of Escherichia coli colonisation factor antigen in acute diarrhoea. Lancet 1978; 2:181-4. (Pubitemid 8385017)
25. Tacket CO, Losonsky G, Link H, et al. Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. N Engl J Med 1988; 318:1240-3.
26. Levine MM, Black RE, Clements ML, Nalin DR, Cisneros L, Finkelstein RA. Volunteer studies in development of vaccines against cholera and enterotoxigenic Escherichia coli: a review. In: Holme T, Holmgren J, Merson MH, Mollby R, eds. Acute enteric infections in children. New prospects for treatment and prevention. Amsterdam: Elsevier/North-Holland Biomedical Press, 1981:443-59.
27. Levine MM, Bergquist EJ, Nalin DR, et al. Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. Lancet 1978; 1:1119-22. (Pubitemid 8356436)
28. Black RE, Levine MM, Clements ML, Hughes TP, Blaser MJ. Experimental Campylobacter jejuni infection in humans. J Infect Dis 1988; 157:472-9. (Pubitemid 18071444)
29. Nash TE, Herrington DA, Levine MM, Conrad JT, Merritt JW Jr. Antigenic variation of Giardia lamblia in experimental human infections. J Immunol 1990; 144:4362-9. (Pubitemid 20187781)
30. Nash TE, Herrington DA, Losonsky GA, Levine MM. Experimental human infections with Giardia lamblia. J Infect Dis 1987; 156:974-84. (Pubitemid 18017076)
31. Neog BK, Barman NN, Bora DP, Dey SC, Chakraborty A. Experimental infection of pigs with group A rotavirus and enterotoxigenic Escherichia coli in India: gross, histopathological and immunopathological study. Vet Ital 2011; 47:117-28.
32. Tzipori S, Chandler D, Makin T, Smith M. Escherichia coli and rotavirus infections in four-week-old gnotobiotic piglets fed milk or dry food. Aust Vet J 1980; 56:279-84.
33. Glass RI, Becker S, Huq I, et al. Endemic cholera in rural Bangladesh, 1966-1980. Am J Epidemiol 1982; 116:959-70. (Pubitemid 13209569)
34. Barua D. ABO blood groups and cholera. Ann Hum Biol 1977; 4:489-92. (Pubitemid 8213191)
35. Harris JB, Khan AI, LaRocque RC, et al. Blood group, immunity, and risk of infection with Vibrio cholerae in an area of endemicity. Infect Immun 2005; 73:7422-7. (Pubitemid 41587645)
36. Faruque AS, Mahalanabis D, Hoque SS, Albert MJ. The relationship between ABO blood groups and susceptibility to diarrhea due to Vibrio cholerae 0139. Clin Infect Dis 1994; 18:827-8. (Pubitemid 24145927)
37. Tacket CO, Losonsky G, Nataro JP, et al. Extension of the volunteer challenge model to study South American cholera in a population of volunteers predominantly with blood group antigen O. Trans R Soc Trop Med Hyg 1995; 89:75-7.
38. Tacket CO, Cohen MB, Wasserman SS, et al. Randomized, doubleblind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with vibrio cholerae O1 El Tor Inaba three months after vaccination. Infect Immun 1999; 67:6341-5.
39. Gitelson S. Gastrectomy, achlorhydria and cholera. Isr J Med Sci 1971; 7:663-7.
40. Nalin DR, Levine MM, Rhead J, et al. Cannabis, hypochlorhydria, and cholera. Lancet 1978; 2:859-62.
41. Nalin DR, Levine RJ, Levine MM, et al. Cholera, non-vibrio cholera, and stomach acid. Lancet 1978; 2:856-9.
42. Hutson AM, Atmar RL, Graham DY, Estes MK. Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis 2002; 185:1335-7. (Pubitemid 34439142)
43. Flores J, Okhuysen PC. Genetics of susceptibility to infection with enteric pathogens. Curr Opin Infect Dis 2009; 22:471-6.
44. Hutson AM, Atmar RL, Marcus DM, Estes MK. Norwalk virus-like particle hemagglutination by binding to h histo-blood group antigens. J Virol 2003; 77:405-15. (Pubitemid 36004980)
45. Lindesmith L, Moe C, Marionneau S, et al. Human susceptibility and resistance to Norwalk virus infection. Nat Med 2003; 9:548-53. (Pubitemid 36597100)
46. Carlsson B, Kindberg E, Buesa J, et al. The G428A nonsense mutation in FUT2 provides strong but not absolute protection against symptomatic GII.4 norovirus infection. PLoS One 2009; 4:e5593.
47. Halperin T, Vennema H, Koopmans M, et al. No association between histo-blood group antigens and susceptibility to clinical infections with genogroup II norovirus. J Infect Dis 2008; 197:63-5. (Pubitemid 351263467)
48. Gill N, Wlodarska M, Finlay BB. Roadblocks in the gut: barriers to enteric infection. Cell Microbiol 2011; 13:660-9.
49. Lievin-Le Moal V, Servin AL. The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota. Clin Microbiol Rev 2006; 19:315-37.
50. Yu LC, Wang JT, Wei SC, Ni YH. Host-microbial interactions and regulation of intestinal epithelial barrier function: from physiology to pathology. World J Gastrointest Pathophysiol 2012; 3:27-43.
51. Stecher B, Hardt WD. Mechanisms controlling pathogen colonization of the gut. Curr Opin Microbiol 2011; 14:82-91.
52. Ivanov II, Littman DR. Modulation of immune homeostasis by commensal bacteria. Curr Opin Microbiol 2011; 14:106-14.
53. Wardwell LH, Huttenhower C, Garrett WS. Current concepts of the intestinal microbiota and the pathogenesis of infection. Curr Infect Dis Rep 2011; 13:28-34.
54. Guarner F, Malagelada Jr. Gut flora in health and disease. Lancet 2003; 361:512-9. (Pubitemid 36173720)
55. Silva SH, Vieira EC, Dias RS, Nicoli Jr. Antagonism against Vibrio cholerae by diffusible substances produced by bacterial components of the human faecal microbiota. J Med Microbiol 2001; 50:161-4. (Pubitemid 32113165)
56. Maier BR, Onderdonk AB, Baskett RC, Hentges DJ. Shigella, indigenous flora interactions in mice. Am J Clin Nutr 1972; 25:1433-40.
57. Levine MM, Hornick RB. Lactulose therapy in Shigella carrier state and acute dysentery. Antimicrob Agents Chemother 1975; 8:581-4.
58. Hansson GC. Role of mucus layers in gut infection and inflammation. Curr Opin Microbiol 2012; 15:57-62.
59. Johansson ME, Phillipson M, Petersson J, Velcich A, Holm L, Hansson GC. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A 2008; 105:15064-9.
60. Moran AP, Gupta A, Joshi L. Sweet-talk: role of host glycosylation in bacterial pathogenesis of the gastrointestinal tract. Gut 2011; 60:1412-25.
61. Bevins CL, Salzman NH. Paneth cells, antimicrobial peptides and maintenance of intestinal homeostasis. Nat Rev Microbiol 2011; 9:356-68.
62. Kinnebrew MA, Pamer EG. Innate immune signaling in defense against intestinal microbes. Immunol Rev 2012; 245:113-31.
63. Willer EM, Lima RL, Giugliano LG. In vitro adhesion and invasion inhibition of Shigella dysenteriae, Shigella flexneri and Shigella sonnei clinical strains by human milk proteins. BMC Microbiol 2004; 4:18.
64. Hayani KC, Guerrero ML, Morrow AL, et al. Concentration of milk secretory immunoglobulin A against Shigella virulence plasmid-associated antigens as a predictor of symptom status in Shigella-infected breast-fed infants. J Pediatr 1992; 121:852-6.
65. Levine MM, Morris JG, Losonsky G, Boedeker E, Rowe B. Fimbriae (pili) adhesins as vaccines. In: Lark DL, Normark S, Uhlin BE, Wolf- Watz H, eds. Protein-carbohydrate interactions in biological systems: the molecular biology of microbial pathogenicity. London: Academic Press, 1986:143-5.
66. Levine MM, Ristaino P, Marley G, et al. Coli surface antigens 1 and 3 of colonization factor antigen II- positive enterotoxigenic Escherichia coli: morphology, purification, and immune responses in humans. Infect Immun 1984; 44:409-20. (Pubitemid 14139007)
67. Levine MM, Black RE, Clements ML, et al. Prevention of enterotoxigenic Escherichia coli diarrheal infection by vaccines that stimulate antiadhesion (antipili) immunity. In: Boedeker EC, ed. Attachment of organisms to the gut mucosa. Boca Raton, FL: CRC Press, 1984:223-44.
68. Levine MM. Escherichia coli that cause diarrhea: enterotoxigenic, enteropathogenic, enteroinvasive, enterohemorrhagic, and enteroadherent. J Infect Dis 1987; 155:377-89. (Pubitemid 17032795)
69. Kotloff KL, Nataro JP, Losonsky GA, et al. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine 1995; 13:1488-94.
70. Ahmed F, Clemens JD, Rao MR, Sack DA, Khan MR, Haque E. Community- based evaluation of the effect of breast-feeding on the risk of microbiologically confirmed or clinically presumptive shigellosis in Bangladeshi children. Pediatrics 1992; 90:406-11.
71. Clemens JD, Stanton B, Stoll B, Shahid NS, Banu H, Chowdhury AK. Breast feeding as a determinant of severity in shigellosis. Evidence for protection throughout the first three years of life in Bangladeshi children. Am J Epidemiol 1986; 123:710-20. (Pubitemid 16104108)
72. Brandtzaeg P. The mucosal immune system and its integration with the mammary glands. J Pediatr 2010; 156(2 suppl):S8-15.
73. Glass RI, Svennerholm AM, Stoll BJ, et al. Protection against cholera in breast-fed children by antibodies in breast milk. N Engl J Med 1983; 308:1389-92. (Pubitemid 13098499)
74. Giugliano LG, Ribeiro ST, Vainstein MH, Ulhoa CJ. Free secretory component and lactoferrin of human milk inhibit the adhesion of enterotoxigenic Escherichia coli. J Med Microbiol 1995; 42:3-9.
75. Walker A. Breast milk as the gold standard for protective nutrients. J Pediatr 2010; 156(2 suppl):S3-7.
76. Kunz C, Rudloff S. Potential anti-inflammatory and anti-infectious effects of human milk oligosaccharides. Adv Exp Med Biol 2008; 606:455-65.
77. Ramachandran M, Vij A, Kumar R, et al. Lack of maternal antibodies to P serotypes may predispose neonates to infections with unusual rotavirus strains. Clin Diagn Lab Immunol 1998; 5: 527-30. (Pubitemid 28342882)
78. Mutanda LN. Epidemiology of acute gastroenteritis in early childhood in Kenya. V. An inverse relationship between the peak age-incidence and the waning of rotavirus maternal antibodies. East Afr Med J 1980; 57:545-8. (Pubitemid 10020524)
79. Fagundes Neto U, Martins MC, Lima FL, Patricio FR, Toledo MR. Asymptomatic environmental enteropathy among slum-dwelling infants. J Am Coll Nutr 1994; 13:51-6. (Pubitemid 24037981)
80. dos Reis JC, de Morais MB, Oliva CA, Fagundes-Neto U. Breath hydrogen test in the diagnosis of environmental enteropathy in children living in an urban slum. Dig Dis Sci 2007; 52:1253-8. (Pubitemid 46626168)
81. Levine MM. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol 2010; 8:129.
82. Looft T, Allen HK. Collateral effects of antibiotics on mammalian gut microbiomes. Gut Microbes 2012; 3:1-5.
83. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 2008; 6:e280.
84. Kelly P. Nutrition, intestinal defence and the microbiome. Proc Nutr Soc 2010; 69:261-8.
85. Levine MM. Immunity to cholera as evaluated in volunteers. In: Ouchterlony O, Holmgren J, eds. Cholera and related diarrheas. Basel: Karger, 1980:195-203.
86. Levine MM, Black RE, Clements ML, et al. The pathogenicity of nonenterotoxigenic Vibrio cholerae serogroup O1 biotype El Tor isolated from sewage water in Brazil. J Infect Dis 1982; 145: 296-9. (Pubitemid 12152120)
87. Donnenberg MS, Tacket CO, James SP, et al. Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection. J Clin Invest 1993; 92:1412-7. (Pubitemid 23273919)